Dyax Corp. to Participate in Upcoming 2013 Healthcare Conferences

  Dyax Corp. to Participate in Upcoming 2013 Healthcare Conferences

RBC Capital Markets Global Healthcare Conference 2013 Cowen Group Healthcare
Conference 2013

Business Wire

BURLINGTON, Mass. -- February 20, 2013

Dyax Corp. (NASDAQ: DYAX) announced today that executive management will
participate in two upcoming conferences, providing a corporate update
regarding the Company’s key value drivers – the KALBITOR^® (ecallantide)
business and the angioedema portfolio, as well as the Licensing and Funded
Research Program (LFRP).

  *George Migausky, Executive Vice President and Chief Financial Officer,
    will present on Tuesday, February 26 at 4:05 PM (ET) at the 2013 RBC
    Capital Markets Healthcare Conference, being held February 26-27, at the
    New York Palace Hotel in New York City.
  *Dr. Ivana Magovcevic-Liebisch, Executive Vice President and Chief
    Operating Officer, will present on Monday, March 4 at 2:50 PM (ET) at the
    Cowen and Company 33^rd Annual Healthcare Conference, being held March 4-6
    at the Boston Marriott Copley Place in Boston, MA.

Both presentations will be webcast live and may be accessed by visiting the
Investor Relations section of the company website at www.dyax.com. The
webcasts will also be available on the Dyax website for a limited period of
time following the conferences.

About Dyax

Dyax is a fully integrated biopharmaceutical company focused on the discovery,
development and commercialization of novel biotherapeutics for unmet medical
needs. The Company’s key value drivers are the KALBITOR^® (ecallantide)
business and the angioedema portfolio, as well as the Licensing and Funded
Research Program (LFRP).

Dyax developed KALBITOR on its own and, since February 2010, the Company has
been selling it in the United States for the treatment of acute attacks of
hereditary angioedema (HAE) in patients 16 years of age and older. Outside the
United States, the Company has established partnerships to obtain regulatory
approval for and commercialization of KALBITOR in certain markets and is
evaluating opportunities in others.

The Company is currently developing products to expand its angioedema
portfolio, including a suite of diagnostic assays to identify plasma
kallikrein mediated (PKM) angioedema and a therapeutic candidate, DX-2930, for
the prophylactic treatment of HAE and PKM angioedemas.

KALBITOR and DX-2930 were identified using Dyax’s patented phage display
technology, which rapidly selects compounds that bind with high affinity and
specificity to therapeutic targets. Dyax leverages this technology broadly
through the LFRP. This program has provided the Company a portfolio of product
candidates being developed by its licensees, which currently includes13
royalty and/or milestone bearing product candidates in various stages of
clinical development, including three in Phase 3 trials.

Dyax is headquartered in Burlington, Massachusetts. For additional information
about Dyax, please visit www.dyax.com.

Contact:

Dyax Corp.
Jennifer Robinson, 617-250-5741
Associate Director, Investor Relations and
Corporate Communications
jrobinson@dyax.com
 
Press spacebar to pause and continue. Press esc to stop.